Drug Database
AT

atorvastatin + ezetimibe (CKD 391 / CKD391)

✓ Approved

Chong Kun Dang Pharmaceutical · HMGCR · 小分子

什么是 atorvastatin + ezetimibe?

atorvastatin + ezetimibe 是一种小分子,由Chong Kun Dang Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名CKD 391, CKD391
公司Chong Kun Dang Pharmaceutical
药物类别小分子
分子靶点HMGCR, NPC1L1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

atorvastatin + ezetimibe 作用于 2 个分子靶点:

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
NPC1L1NPC1 like intracellular cholesterol transporter 1 (SLC65A2, LDLCQ7)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

atorvastatin + ezetimibe 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Metabolism and nutrition disordersHyperlipidaemia✓ Approved

相关研究文献

PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-11-18

Lipid-lowering, antioxidant, and anti-inflammatory effects of Erythrina speciosa and its triterpenoids in acute dyslipidemia.

Elsayed Rasha H RH, El-Toumy Sayed A SA, Kamel Emadeldin M EM, Ahmed Sayed A SA et al.

Dyslipidemia is a health concern that contributes to metabolic and cardiovascular complications. The present study evaluated the anti-dyslipidemic potential of the chloroform fraction of Erythrina speciosa leaves and its isolated constituents, with particular emphasis on lipid regulation, redox balance, and inflammatory mediators. Chromatographic separation of the chloroform fraction led to the isolation of five triterpenoids, reported here for the first time from E. speciosa. The biological activity was assessed in a poloxamer-407-induced acute hyperlipidemia model in rats. Treatment with the chloroform fraction, isolated compounds, or atorvastatin significantly attenuated elevations in serum total cholesterol and triglycerides and improved low-density lipoprotein-cholesterol (LDL-C). These effects were accompanied by restoration of lipoprotein lipase (LPL) activity, upregulation of hepatic LDL receptor (LDL-R), downregulation of fatty acid synthase (FAS), and suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) reductase. Moreover, E. speciosa and its triterpenoids markedly alleviated oxidative stress and inflammation, as evidenced by reduced malondialdehyde (MDA), nitric oxide (NO), nuclear factor-kappaB (NF-κB) p65, tumor necrosis factor (TNF)-α, and interleukin (IL)- 1β and enhanced antioxidants. Molecular docking provided supportive computational evidence by predicting favorable binding interactions of the isolated compounds with NF-κB p65, LDL-R PCSK9 binding domain, and FAS. In conclusion, E. speciosa and its triterpenoids are promising candidates for the management of dyslipidemia and related inflammatory and oxidative disturbances.

PMID 43045819
阅读全文 →
PubMedMemorias do Instituto Oswaldo Cruz2026-11-18

Contributions of the FIOCHAGAS network partnership between medicinal chemistry and parasitology groups through repurposing new drug candidates for Chagas diseaseFIRST REVIEW ROUND - REVIEWERS COMMENTSSECOND REVIEW ROUND - REVIEWERS COMMENTSTHIRD REVIEW ROUND - REVIEWERS COMMENTSFOURTH REVIEW ROUND - REVIEWERS COMMENTS.

Soeiro Maria de Nazaré Correia MNC, Bastos Monica M MM, Menozzi Cheyene Ac CA, Simões-Silva Marianne R MR et al.

Chagas disease (CD) is a tropical neglected disease caused by the protozoan Trypanosoma cruzi. The therapy based on two nitro derivatives is outdated, exhibits toxicity and has limited efficacy. This report reviews the successful interaction of multidisciplinary teams of medicinal chemistry, pharmacology and parasitology research groups belonging to FIOCHAGAS program, with the goal of finding new drug candidates for CD. Based on drug repositioning and combination strategies, drug candidates acting on different mechanisms of action, such as (i) tyrosine kinase inhibitors (imatinib - IMB) and (ii) ergosterol biosynthesis inhibitors (atorvastatin - AVA), were investigated in non-clinical studies to detect anti-T. cruzi activity/selectivity as well as ADMET and safety profile. These studies (in silico and in vitro,) were guided by standardised protocols, constructed from a flowchart that identifies promising candidates for the treatment of CD. Despite the known limited efficacy of several statins in monotherapy approach, AVA-aminoquinoline hybrids emerged as promising antiparasitic agents, developed through a synthetic pharmaceutical innovation platform that combines molecular hybridisation and phenotypic approaches. IMB and derivatives represent another successful example of drug repositioning, revealing antitrypanosomal activity through the modulation of kinase-related pathways relevant to T. cruzi infection. One of them, LS2/89 reached EC50 of 0.19 μM, being about 22-fold more potent than BZ, with the high selectivity index (65) over mammalian cells. LS2/89 was the most potent against bloodstream forms displaying EC50 of 2.67 μM, being over 5-fold more active than BZ. The positive interaction between multidisciplinary groups, acting as interactive partners in the application of repositioning along with drug combinations, represents a faster and more economical strategy. These studies allow the identification of new therapeutic alternatives with efficacy/safety profiles equal to or superior to those of reference drugs, contributing to drug discovery process against this threatening disease.

PMID 43049016
阅读全文 →
PubMedAtherosclerosis plus2026-11-16

Simulation of low-density lipoprotein cholesterol goal attainment with treatment intensification in a population with homozygous familial hypercholesterolemia.

Koumas Alexandra A, Sriprada Tupili Sravya TS, Sanchez Robert J RJ, Tripathi Sandeep S et al.

Most people with homozygous familial hypercholesterolemia (HoFH) do not achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals despite standard-of-care (SOC) lipid-lowering therapies (LLTs). Here, we estimate the proportion of individuals with HoFH achieving guideline-recommended LDL-C goals of <100 mg/dL, <70 mg/dL, and <55 mg/dL after treatment intensification. A simulation model explored LLT intensification strategies with statin, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is), evinacumab, lomitapide, and/or lipoprotein apheresis for LDL-C goal attainment. Baseline LLTs and LDL-C levels were obtained from 78 participants with HoFH in the CASCADE FH registry. Adding evinacumab or lomitapide (10 mg/day) to SOC enabled an estimated 80.1% and 59.3% of individuals to reach LDL-C <100 mg/dL, respectively; biweekly apheresis plus SOC enabled 65.4%. Combining evinacumab and apheresis with SOC raised attainment of <100 mg/dL to 95.6%, and adding lomitapide further increased attainment to 96.7%. For more stringent goals of LDL-C <70 mg/dL and <55 mg/dL, 50.9% and 29.8% of individuals achieved these goals with evinacumab plus SOC, respectively, and 80.8% and 64.6% with evinacumab and apheresis plus SOC. Combining all three advanced therapies (evinacumab, lomitapide, and apheresis) with SOC enabled most people to reach goals of <70 mg/dL (92.4%) and <55 mg/dL (79.7%). Simulation findings indicate that most people with HoFH require aggressive treatment intensification with advanced LLTs to achieve guideline-recommended LDL-C goals. Evinacumab with/without apheresis or lomitapide represents a highly effective treatment strategy. Our findings support earlier escalation to advanced LLTs when SOC is unlikely to be sufficient.

PMID 43036356
阅读全文 →
PubMedPloS one2026-11-16

Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study.

Dang Hai Nguyen Ngoc HNN, Nguyen Hung Minh HM, Tran Phuc Thien PT, Ho Binh Anh BA et al.

Guideline-directed medical therapy is central to secondary prevention after acute coronary syndrome (ACS), but recommendations are usually framed at the medication-class level. In discharge practice, clinicians must select individual agents, especially in older patients with multivessel coronary disease. This study described discharge prescribing patterns and examined associations between within-class medication choices and short-term major adverse cardiovascular events (MACE). This prospective, multicenter, real-world observational cohort included 277 patients aged ≥60 years with ACS and multivessel coronary disease. The primary outcome was 3-month MACE. Risk ratios (RRs) were estimated using modified Poisson regression with robust standard errors. Core secondary prevention therapies were frequently prescribed, including dual antiplatelet therapy in 99.3% and statins in 99.6%. In fully adjusted within-class analyses, ticagrelor versus clopidogrel had an RR of 0.70 for short-term MACE (95% CI, 0.40-1.21; P = 0.203), empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93-2.59; P = 0.094), and rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79-1.85; P = 0.372). Exploratory subgroup analyses showed nominal signals for ticagrelor versus clopidogrel among patients with frailty (RR, 0.36; 95% CI, 0.15-0.89; P = 0.026), and for empagliflozin versus dapagliflozin among patients with left ventricular ejection fraction <50% (RR, 1.86; 95% CI, 1.07-3.21; P = 0.027) and non-ST-segment elevation acute coronary syndrome (RR, 2.26; 95% CI, 1.05-4.88; P = 0.037). However, none remained statistically significant after adjustment for multiple comparisons. In older patients with ACS and multivessel disease, secondary prevention was widely implemented. Within-class comparisons showed no clear short-term MACE differences, while subgroup signals require validation.

PMID 43038200
阅读全文 →
PubMedIntegrative medicine research2026-11-15

Pharmacokinetic interactions between atorvastatin and traditional herbal medicines, Banhabaekchulcheonmatang and Hwangryeonhaedoktang in healthy volunteers.

Song Jungbin J, Cho Seok-Jin SJ, Kang Dong Wook DW, Kim Ju Hee JH et al.

Banhabaekchulcheonmatang (BBCT) and Hwangryeonhaedoktang (HRHDT) are traditional herbal medicines widely used in East Asia to treat post-stroke sequelae. This study evaluated the effects of BBCT and HRHDT on the pharmacokinetics of atorvastatin, a drug commonly prescribed for secondary stroke prevention. An open-label, randomized, three-period, two-sequence trial was conducted in 14 healthy Korean participants. In the first period, participants received a single 40 mg dose of atorvastatin. In subsequent periods, BBCT or HRHDT was administered three times daily for five days, followed by co-administration with atorvastatin on day 6. Plasma concentrations of atorvastatin and its active metabolites were measured, and pharmacokinetic parameters were determined using non-compartmental analysis. Co-administration of BBCT reduced the maximum plasma concentration (Cmax) of atorvastatin by 24% without affecting the area under the plasma concentration-time curve (AUC), whereas HRHDT decreased atorvastatin Cmax, AUClast, and AUCinf by 46.7%, 22.6%, and 21.1%, respectively. BBCT or HRHDT co-administration also reduced the Cmax, AUClast, and AUCinf of 2-hydroxy atorvastatin by 30.2% and 52.7%, 14.9% and 35.9%, and 14.8% and 32.0%, respectively. Co-administration of atorvastatin with BBCT or HRHDT resulted in a weak-to-moderate reduction in systemic exposure to atorvastatin and 2-hydroxy atorvastatin, suggesting that careful monitoring may be warranted during concomitant use. Clinical Research Information Service (CRIS), Republic of Korea (KCT0008735).

PMID 43034617
阅读全文 →
PubMedFrontiers in pharmacology2026-11-15

Atorvastatin-associated liver injury: a structured narrative review of reporting signals, clinical phenotypes, and hepatic safety, 2023-2026.

Zhang Hao H, Zhao PanLi P, Huang Hua H, Zeng YuQi Y

Atorvastatin is widely prescribed, yet its hepatic safety remains debated: randomized trials and biopsy-proven cohorts indicate acceptable safety, whereas pharmacovigilance data and case reports describe injury ranging from asymptomatic transaminase elevation to acute liver failure. PubMed was searched for records combining atorvastatin terms with liver-injury concepts, published 1 July 2023 to 31 July 2026; records were screened in duplicate and assigned to one of four outcome domains-biochemical liver test abnormality, suspected drug-induced liver injury (DILI), clinically significant or severe DILI, and acute liver failure-and were not combined across domains. This is a structured narrative review, not a systematic review: only PubMed was searched and comprehensive retrieval is not claimed. Of 119 records, 57 were included in the synthesis: 31 directly addressed atorvastatin and liver injury and 26 addressed statin hepatic safety or statin use in chronic liver disease. Among 7,779 statin-associated drug-induced liver injury (DILI) cases in FAERS (2004-2023), atorvastatin accounted for 53.48%, with a reporting odds ratio of 3.09. In 1 211 reported Chinese cases of statin-associated liver injury, the odds of severe injury were 1.77-fold higher with atorvastatin than with rosuvastatin, and 2.08-fold higher with combination therapy than with statin monotherapy. Phenotypes included hepatocellular, cholestatic and mixed injury, drug-induced autoimmune hepatitis (DIAIH) and hyperacute liver failure, usually within 2-3 months. Rechallenge reproduced injury in 12 of 16 cases, with median latency shortened from 27 to 11 days, whereas switching to a hydrophilic statin was usually tolerated. Mechanisms involve mitochondrial dysfunction, oxidative stress, CYP3A-mediated metabolic activation, bile-acid transporter inhibition and pharmacogenomic variation. Conversely, in MASLD and cirrhosis, atorvastatin did not worsen liver injury and reduced liver-related events. Severe atorvastatin-associated liver injury is rare but recognizable. Structured monitoring, causality assessment and injury phenotyping are essential, same-drug rechallenge should be avoided, and hydrophilic statins preferred. Statin therapy should not be withheld in chronic liver disease.

PMID 43032608
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多atorvastatin + ezetimibe